282 related articles for article (PubMed ID: 24397165)
21. Optimizing the diabetic formulary: beyond aspirin and insulin.
Marso SP
J Am Coll Cardiol; 2002 Aug; 40(4):652-61. PubMed ID: 12204494
[TBL] [Abstract][Full Text] [Related]
22. [Arterial risk in type 2 diabetes: from mega-trials to prescription].
Bonnet F; Moulin P
Rev Prat; 2003 May; 53(10):1095-101. PubMed ID: 12846030
[TBL] [Abstract][Full Text] [Related]
23. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
Duntas L; Kolovou G
Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018
[No Abstract] [Full Text] [Related]
24. Effect of a multifactorial intervention on mortality in type 2 diabetes.
Gaede P; Lund-Andersen H; Parving HH; Pedersen O
N Engl J Med; 2008 Feb; 358(6):580-91. PubMed ID: 18256393
[TBL] [Abstract][Full Text] [Related]
25. Does aspirin use reduce cardiovascular risk in diabetes?
Colwell JA
Nat Rev Endocrinol; 2009 Apr; 5(4):188-90. PubMed ID: 19352314
[TBL] [Abstract][Full Text] [Related]
26. Aspirin for primary prevention of cardiovascular events in people with diabetes.
Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS; ; ;
J Am Coll Cardiol; 2010 Jun; 55(25):2878-86. PubMed ID: 20579547
[No Abstract] [Full Text] [Related]
27. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
28. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
29. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
30. Is treatment of hypertension with acetylcholine esterase inhibitors (ACEIs) superior to other antihypertensives in preventing significant cardiovascular events and death in patients with type 2 diabetes?
McConaghy JR
J Fam Pract; 2000 Nov; 49(11):980. PubMed ID: 11093559
[No Abstract] [Full Text] [Related]
31. Glycemic targets for patients with type 2 diabetes mellitus.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular diseases and diabetes mellitus.
Bandyopadhyay P
Drug News Perspect; 2006; 19(6):369-75. PubMed ID: 16971974
[TBL] [Abstract][Full Text] [Related]
33. Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".
Paraskevas KI
J Vasc Surg; 2008 Sep; 48(3):776-7; author reply 777. PubMed ID: 18727983
[No Abstract] [Full Text] [Related]
34. Trials of cardiovascular risk factor management in type 2 diabetes.
Patel A; Joshi R; de Galan B
Curr Opin Cardiol; 2009 Jul; 24(4):288-94. PubMed ID: 19322080
[TBL] [Abstract][Full Text] [Related]
35. [Dangerous duo: hypertension and pre-diabetes--the underestimated risk].
MMW Fortschr Med; 2003 Jan; 145(3-4):54-5. PubMed ID: 12619235
[No Abstract] [Full Text] [Related]
36. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
Lièvre M
Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
[TBL] [Abstract][Full Text] [Related]
37. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
38. Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Grimes RT; Ensor J; Bennett K; Henman MC
Prim Care Diabetes; 2016 Aug; 10(4):237-43. PubMed ID: 26654852
[TBL] [Abstract][Full Text] [Related]
39. [Diabetes mellitus and cerebrovascular disorders].
Udaka F
Nihon Rinsho; 2002 Oct; 60 Suppl 10():336-41. PubMed ID: 12430250
[No Abstract] [Full Text] [Related]
40. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.
Yki-Järvinen H
Drugs; 2000 Nov; 60(5):975-83. PubMed ID: 11129129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
